Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01391689 · ClinicalTrials.gov registry record · NA
Diindolylmethane in Treating Patients With Breast Cancer
A NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT01391689 is a NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer that has completed, run by University of Arizona. The registered enrollment target is 144 participants, below the 314-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01391689, a NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II/III trial studies how well diindolylmethane (DIM) works and compares it to placebo in treating patients with breast cancer. DIM may slow the growth of tumor cells and be an effective treatment for breast cancer.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT diindolylmethane
Study Locations (1)
Arizona
- Arizona Cancer Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2011-02 |
| Est. Completion | 2016-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01391689
The ClinicalTrials.gov registry entry for NCT01391689 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 314-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (54% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01391689 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01391689 about?
NCT01391689 is a clinical study titled "Diindolylmethane in Treating Patients With Breast Cancer". This phase II/III trial studies how well diindolylmethane (DIM) works and compares it to placebo in treating patients with breast cancer. DIM may slow the growth of tumor cells and be an effective treatment for breast cancer.
What is the current status of trial NCT01391689?
This trial is currently completed. It is a NA study. The enrollment target is 144 participants. The study started on 2011-02. Estimated completion is 2016-07-31.
What conditions does trial NCT01391689 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer.
What interventions are being tested in trial NCT01391689?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), diindolylmethane (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01391689?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01391689 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
ACTIVE NOT RECRUITING · NA
-
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ACTIVE NOT RECRUITING · NA
-
Researching the Effect of Exercise on Cancer
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.